Thyroid cancer is the most common endocrine malignancy giving rise to one of the most
indolent solid cancers, but also one of the most lethal. In recent years, systematic studies of …

Purpose Our study aimed to describe the evolution of the rate of pathological subtypes of
well-differentiated follicular-cell derived thyroid carcinomas (DTCs) in the Department of …

During the last decades the knowledge on follicular cell-derived thyroid cancer (TC)
molecular biology has led to the evolution of a number of novel therapies for these tumors …

The majority of patients with differentiated thyroid cancer are cured with standard primary
treatments including surgery, radioactive iodine and TSH suppression. A small proportion of …

Well-differentiated thyroid carcinoma remains a relatively uncommon diagnosis with a
favorable prognosis. Treatment algorithms continue to evolve with the emergence of new …

Differentiated thyroid cancer (DTC) accounts for 98% of thyroid cancer, with neoplasms
arising from the follicular cells (papillary, follicular and Hurthle cell thyroid cancer) and …

In this contribution, we review the limitations of the currently applied standard treatments for
well-differentiated, non-medullary thyroid cancer (ThyrCa), and describe the molecular and …

Thyroid cancer is the most common endocrine malignancy. Differentiated thyroid cancer
(DTC) with the two subtypes, papillary thyroid cancer (PTC) and follicular thyroid cancer …

Normally, thyroid cancer is a disease with a good prognosis, but about 30% of the tumours
dedifferentiate and may finally develop into highly malignant anaplastic thyroid carcinomas …

This review summarizes the changes in the 5th edition of the WHO Classification of
Endocrine and Neuroendocrine Tumors that relate to the thyroid gland. The new …